RSS Feeds
Thrombolysis and Ventricular Tachycardia
- Paul E. Nathan, MD; and
- Terrence J. Sacchi, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
In a recent study, Eldar and associates [1] pointed out that patients with and without primary ventricular tachycardia do not differ in their hospital course and 1-year prognosis.
What patients, if any, received thrombolytic therapy during the acute myocardial infarction? Bourke and colleagues [2] did electrophysiologic testing in 87 patients 6 to 28 days after myocardial infarction and found, compared with placebo, intravenous streptokinase substantially reduced the incidence of inducible ventricular tachycardia without similar benefit attributable to aspirin therapy.
It is not clear what significance monomorphic or polymorphic primary ventricular tachycardia have in patients who have received thrombolytic therapy compared with those who have not. Did these arrhythmias merely identify reperfusion in patients receiving lytic agents? What effect did the administration of these agents have on the true incidence of this arrhythmia in this cohort? It seems that these issues deserve further investigation.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
- Copyright ©2004 by the American College of Physicians
